Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Boehringer Ingelheim Secures Global Rights to Immunitas’ First-in-Class Antibody Program for Chronic Inflammatory Diseases in €407.5M Deal

Fineline Cube May 13, 2026
Company Deals

Mindray Bio-Medical Re-Files for Hong Kong Listing After Initial Application Expiration

Fineline Cube May 12, 2026
Company Deals

Akari Therapeutics Partners with WuXi XDC to Advance Novel PH1 Payload Platform for Urothelial Cancer

Fineline Cube May 12, 2026
Company Deals

China Medical System Secures Exclusive China Rights to Pharmacosmos’ MonoFer and CosmoFer IV Iron Therapies

Fineline Cube May 12, 2026
Company Deals

Yifan Pharmaceutical Licenses Ryzneuta to French Distributor Intsel Chimos for Exclusive Commercialization

Fineline Cube May 12, 2026
Policy / Regulatory

Hong Kong to Launch FDA-Style Medical Products Regulation Center by Year-End, Creating Gateway for Chinese Innovative Drugs

Fineline Cube May 13, 2026
Company Drug

ImmuneOnco Receives NMPA Approval for IMM0306 Clinical Study in Primary Sjögren’s Syndrome, Expanding Dual-Target Bispecific Platform

Fineline Cube May 13, 2026
Company Drug

Alphamab Oncology Initiates Phase II Trial of Subcutaneous Co-Formulation JSKN033 in First-Line Advanced Cervical Cancer

Fineline Cube May 13, 2026
Company Drug

XellSmart Bio-Pharmaceutical Achieves Milestone with First Patient Enrollment in Global iPSC Clinical Study for ALS

Fineline Cube Nov 30, 2024

XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd., in collaboration with Shanghai East Hospital (Tongji University Affiliated East...

Company Drug

Cutia Therapeutic’s CU-20401 Shows Positive Results in Phase II Subcutaneous Fat Reduction Study

Fineline Cube Nov 29, 2024

China-based dermatology specialist Cutia Therapeutic (HKG: 2487) has revealed a positive readout from its Phase...

Company Deals

OBiO Technology Partners with Hanxin Biotechnology to Advance LNP Delivery System

Fineline Cube Nov 29, 2024

China-based gene therapy Contract Research Organization (CRO) OBiO Technology (Shanghai) Co., Ltd (SHA: 688238) has...

Company Medical Device

NMPA Approves Shenzhen Mindray’s Innovative Dual-Mode Ultrasound Diagnostic System

Fineline Cube Nov 29, 2024

The National Medical Products Administration (NMPA) has granted approval to Shenzhen Mindray Bio-Medical Electronics Co.,...

Company Medical Device

NMPA Approves Hangzhou Ruidi Biotechnology’s Steep Pulse Therapy Equipment for Tumor Treatment

Fineline Cube Nov 29, 2024

China’s National Medical Products Administration (NMPA) has granted approval to Hangzhou Ruidi Biotechnology Co., Ltd...

Company Drug

CDE Expands Care Plan with Approvals for Ractigen’s RAG-17 and Vitalgen’s VGR-R01

Fineline Cube Nov 29, 2024

In a swift succession of actions, China’s Center for Drug Evaluation (CDE) has added two...

Policy / Regulatory

NMPA Drafts Medical Representative Management Measures, Seeks Public Input

Fineline Cube Nov 29, 2024

The National Medical Products Administration (NMPA) has released the “Medical Representative Management Measures (draft proposal)”,...

Company Deals

Daiichi Sankyo Invests RMB 1.1 Billion in New ADC Manufacturing Plant in Shanghai

Fineline Cube Nov 29, 2024

Japanese pharmaceutical company Daiichi Sankyo (TYO: 4568) is significantly increasing its investment in China with...

Company Drug

Jiangsu Kanion Pharmaceutical Gets NMPA Clearance for Oncolytic Virus Product KYS202003A

Fineline Cube Nov 29, 2024

Jiangsu Kanion Pharmaceutical Co., Ltd (SHA: 600557) has announced that it has received clinical clearance...

Company Deals

Lingyi Biotechnology and Jolly Pharmaceutical Ink Comprehensive Collaboration Agreement

Fineline Cube Nov 29, 2024

China-based gene therapy specialist Lingyi Biotechnology Co., Ltd has entered into a comprehensive collaboration agreement...

Company Drug

Sichuan Biokin Pharmaceutical’s BL-M08D1 ADC Receives NMPA Approval for Clinical Trials

Fineline Cube Nov 29, 2024

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a China-based pharmaceutical company, has announced that it...

Company Deals

Huadong Medicine Receives FDA Clearance for HDM1005 Clinical Study in Obstructive Sleep Apnea

Fineline Cube Nov 29, 2024

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received clearance from...

Company Drug

Laekna, Inc. Initiates IND-Enabling Study for Monoclonal Antibody LAE123 in Severe Diseases

Fineline Cube Nov 29, 2024

Sino-US biotech company Laekna, Inc. (HKG: 2105) has announced the initiation of an Investigational New...

Company Deals

CORXEL Partners with Apeloa Pharmaceutical for CDMO Services Expansion

Fineline Cube Nov 29, 2024

China-based contract development and manufacturing organization (CDMO) Apeloa Pharmaceutical Co., Ltd (SHE: 000739) has announced...

Company Deals

Wuhan Union Hospital to Transfer Hereditary Thrombophilia Detection Patent to Kingmed Diagnostics

Fineline Cube Nov 29, 2024

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, also recognized as Wuhan...

Company Deals

Shanghai Yanyin Technology Partners with Castalysis Bioscience to Advance CRISPR Software Development

Fineline Cube Nov 29, 2024

Shanghai Yanyin Technology Co., Ltd has announced a strategic partnership with Castalysis Bioscience (Shanghai), a...

Company Drug

Eisai and Biogen Launch Alzheimer’s Treatment Leqembi in South Korea

Fineline Cube Nov 29, 2024

Partners Eisai Co., Ltd (TYO: 4523) and Biogen Inc. (NASDAQ: BIIB) have jointly announced the...

Company

Bayer AG Launches Bayer Co.Lab Berlin, Focusing on Life Science Innovation

Fineline Cube Nov 29, 2024

Germany-based Bayer AG (ETR: BAYN) has announced the opening of its new life science incubator,...

Policy / Regulatory

Chinese Pharmacopoeia Commission Approves Draft for ChP 2025 Edition

Fineline Cube Nov 29, 2024

On December 27, the 12th Conference of the Chinese Pharmacopoeia Commission (ChPC) Executive Committee concluded...

Company Drug

Huadong Medicine’s Arcalyst Receives NMPA Approval for Cryopyrin-Associated Periodic Syndromes

Fineline Cube Nov 28, 2024

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced receiving marketing approval from the National...

Posts pagination

1 … 255 256 257 … 664

Recent updates

  • ImmuneOnco Receives NMPA Approval for IMM0306 Clinical Study in Primary Sjögren’s Syndrome, Expanding Dual-Target Bispecific Platform
  • Bayer Reports 4.1% Q1 Sales Growth to €13.4B, with Mixed Pharmaceutical Performance Amid IRA Impact and Generic Competition
  • Boehringer Ingelheim Secures Global Rights to Immunitas’ First-in-Class Antibody Program for Chronic Inflammatory Diseases in €407.5M Deal
  • Roche Secures CE Mark for Elecsys pTau217 Blood Test, First Single-Assay Alzheimer’s Diagnostic with Amyloid Pathology Detection
  • Alphamab Oncology Initiates Phase II Trial of Subcutaneous Co-Formulation JSKN033 in First-Line Advanced Cervical Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

ImmuneOnco Receives NMPA Approval for IMM0306 Clinical Study in Primary Sjögren’s Syndrome, Expanding Dual-Target Bispecific Platform

Others

Bayer Reports 4.1% Q1 Sales Growth to €13.4B, with Mixed Pharmaceutical Performance Amid IRA Impact and Generic Competition

Company Deals

Boehringer Ingelheim Secures Global Rights to Immunitas’ First-in-Class Antibody Program for Chronic Inflammatory Diseases in €407.5M Deal

Company Medical Device

Roche Secures CE Mark for Elecsys pTau217 Blood Test, First Single-Assay Alzheimer’s Diagnostic with Amyloid Pathology Detection

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.